Receives FDA Orphan Drug Designation for Eniluracil in Liver Cancer
More News related to ADH
- Adherex (ADH) Announces 2 Presentations of ADH-1 Data at Annual Meeting
- Adherex Technologies (ADX) Initiates Phase I Combination Trials for Treatment of Melanoma
- Adherex Technologies (ADH) Regains All Rights to ADH-1 and Will Continue Clinical Development
- Receives FDA Orphan Drug Designation for Eniluracil in Liver Cancer
- ADH Receives Investigational New Drug 'IND' Clearance
Adherex Technologies Inc. (AMEX: ADH) received orphan drug designation for eniluracil from the FDA. The designation was granted for the use of eniluracil in combination with fluoropyrimidines for the treatment of hepatocellular cancer. The fluoropyrimidines include 5-fluorouracil (5-FU) and other 5-FU prodrugs. Adherex's global development plans for eniluracil, announced on November 16, 2005, include clinical trials in hepatocellular cancer.
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
